First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria
Otto, F; Bajer-Kornek, B; Rommer, P; Leutmezer, F; Franta-Elmer, C; Oel, D; Latzko, C; Sellner, J
J NEUROL SCI. 2017; 381: 796-796.
Abstracts (Zeitschrift)